Pricing Log in Create free account

ImmunityBio, Inc. (IBRX) vs TG Therapeutics, Inc. (TGTX)

ImmunityBio, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. ImmunityBio, Inc. and TG Therapeutics, Inc. are of similar size ($8.9B and $8.5B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.1×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 76.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs −598.6%) and the higher return on invested capital (10.7% vs 0.00%). Across the 17 metrics below, TG Therapeutics, Inc. leads on 11 and ImmunityBio, Inc. on 6.

Valuation

Metric IBRX TGTX Biotechnology median
P/E n/m 19.11 10.26
P/S 51.05 10.30 9.18
P/B n/m 13.64 2.05
Price to free cash flow n/m 473.79 24.81
EV/EBITDA n/m 62.00 0.65
EV/Sales 56.47 10.54 8.98
Earnings yield (12.03%) 5.23% (34.89%)
Free cash flow yield (3.40%) 0.21% (24.52%)

Profitability

Metric IBRX TGTX Biotechnology median
Gross margin 99.34% 82.37% 65.16%
Operating margin (151.88%) 17.05% 0.00%
Net margin (598.56%) 55.22% 0.00%
Free cash flow margin (173.76%) 2.17% 0.00%
Return on equity 122.85% 100.28% (50.12%)
Return on assets (192.58%) 37.70% (45.60%)
Return on invested capital 0.00% 10.69% 0.00%

Growth

Metric IBRX TGTX Biotechnology median
Revenue growth (TTM) 192.92% 76.08% 6.26%
EPS growth (last fiscal year) 38.71% 1,746.67% 29.88%
Revenue growth, 5-year CAGR 184.76% 426.73% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IBRX TGTX Biotechnology median
Debt to equity (0.74) 1.23 0.00
Current ratio 5.72 4.27 4.89
Net debt to EBITDA (0.97) 0.86 1.01

Dividend

Metric IBRX TGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IBRX TGTX Biotechnology median
Market cap 8.49b 8.87b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack